Dermatology · Chula Vista, CA
NPI
1811422801
Since 2017
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
256 Landis Ave Ste 300
Chula Vista, CA, 91910
Phone (619) 426-9600
Groups this clinician bills Medicare through
Medicare paid, 2024
$460K
8,504 services
Medicare patients, 2024
495
Average age 76
Drug cost, 2024
$1.0M
2,737 prescriptions
Company payments, 2025
$6,554
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jacqueline McKesey was code 17003 (destruction skin lesion), 2,347 times for 238 patients. In total Jacqueline McKesey billed 8,504 services in 96 codes, and Medicare paid $460K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-06-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,347 | 238 | $5.93 | $14K |
| 99214 Office E&M - Established | Office | 1,047 | 330 | $101.05 | $106K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 512 | 176 | $0.75 | $385 |
| 17000 Destruction Skin Lesion | Office | 496 | 268 | $37.34 | $19K |
| 99213 Office E&M - Established | Office | 428 | 187 | $72.46 | $31K |
| 17110 Destruction Skin Lesion | Office | 427 | 243 | $93.51 | $40K |
| 96372 Injection Administration | Office | 257 | 63 | $12.08 | $3,104 |
| 11102 Skin Biopsy | Office | 254 | 173 | $67.46 | $17K |
| 97597 Debridement | Office | 185 | 52 | $88.08 | $16K |
| 11901 Skin | Office | 181 | 84 | $45.00 | $8,144 |
| 11103 Skin Biopsy | Office | 165 | 82 | $44.41 | $7,328 |
| 11900 Skin | Office | 142 | 92 | $31.13 | $4,421 |
| 99212 Office E&M - Established | Office | 116 | 78 | $46.09 | $5,346 |
| 17004 Destruction Skin Lesion | Office | 115 | 78 | $142.86 | $16K |
| 99204 Office E&M - New | Office | 69 | 69 | $113.63 | $7,840 |
By year: 2022 $68K for 1,265 services; 2023 $350K for 6,152 services; 2024 $460K for 8,504 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jacqueline McKesey prescribed most often to Medicare patients was Ketoconazole, with 645 prescriptions and refills. In total Jacqueline McKesey wrote 2,737 Medicare prescriptions that cost $1.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 645 | 685 | 264 | $13K |
| Fluocinonide Generic | 268 | 282 | 132 | $10K |
| Hydrocortisone Generic | 219 | 219 | 133 | $1,210 |
| Triamcinolone Acetonide Generic | 217 | 245 | 124 | $2,803 |
| Doxycycline Monohydrate Generic | 135 | 137 | 104 | $989 |
| Betamethasone Dipropionate Generic | 121 | 129 | 54 | $5,440 |
| Mupirocin Generic | 115 | 117 | 73 | $702 |
| Clobetasol Propionate Generic | 102 | 104 | 51 | $3,518 |
| Opzelura Ruxolitinib Phosphate | 101 | 101 | 28 | $188K |
| Tacrolimus Generic | 98 | 101 | 47 | $9,922 |
| Zoryve Roflumilast | 53 | 53 | 17 | $43K |
| Clindamycin Phosphate Generic | 45 | 45 | 21 | $1,341 |
| Hydroxyzine Hcl Generic | 44 | 53 | 21 | $270 |
| Terbinafine Hcl Generic | 40 | 54 | 24 | $241 |
| Ciclopirox Generic | 36 | 38 | 14 | $1,197 |
Brand drugs: 291 claims; generic drugs: 2,446 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jacqueline McKesey $6,554 ($6,554 in general payments such as food, travel and fees) from 22 companies. The largest payer was Incyte Corporation with $3,299.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 34 | $3,299 |
| Janssen Biotech, Inc. JNJ | 31 | $778 |
| Abbvie Inc. ABBV | 17 | $540 |
| Genzyme Corporation SNY | 9 | $302 |
| Galderma Laboratories, L.P. GALD.SW | 11 | $246 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 8 | $213 |
| Arcutis Biotherapeutics, Inc. ARQT | 12 | $164 |
| LEO Pharma Inc. | 8 | $149 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $132 |
| Pfizer Inc. PFE | 5 | $120 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.